RedChip Companies
|
Weekly Newsletter
|
|
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
|
Soligenix (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced preliminary top-line results of its ongoing Phase 2a trial of SGX302 (synthetic hypericin) for the treatment of mild-to-moderate psoriasis. In the expanded portion of the trial (Cohort 2), an additional five patients were enrolled and the treatment guidelines for use of light activation were adjusted to allow for a more rapid escalation and higher final dose level of light than in the initial cohort of patients, which is expected to more closely mirror the way the drug will eventually be used in a "real world" clinical setting.
For more information, visit www.soligenix.com
|
American Resources Corporation's Affiliated Company, Novusterra Inc., Announces Strategic Partnership with Kenai Defense, Texas Tech University, and the United States Air Force
American Resources (Nasdaq: AREC), a next generation and socially responsible supplier of rare earth and critical elements, carbon and advanced carbon materials to the new infrastructure and electrification marketplace, announced that their affiliated company, Novusterra Inc. (Private) ("Novusterra") a company specializing in the development and production of carbon nanomaterials and graphene to the infrastructure, agriculture, and electrification economy, announced that its patented technology to produce carbon nanomaterial additives for concrete and asphalt pavements is being used as the exclusive patented technology in a comprehensive research project to improve the future durability of airfields for the United States Air Force.
|
Everything Blockchain Inc. Launches EB Control Enterprise
Everything Blockchain (OTC: EBZT), a technology company that is blending blockchain, DBMS and Zero Trust to deliver disruptive new ways to store, manage and protect data, has launched EB Control Enterprise. Expanding upon the celebrated EB Control platform, EB Control Enterprise will feature an enhanced centralized management portal, empowering companies to perform comprehensive enterprise management and reporting on a larger scale. EB Control Enterprise now also plugs seamlessly into enterprise IT workflows such as Active Directory ADFS and adds support for FIDO 2 and SAML.
|
|
|
Royalty Management Holding Corporation 2023 Year End Shareholder Letter
Royalty Management (Nasdaq: RMCO), an innovative royalty company building shareholder value by acquiring and developing high value assets in a sustainable market environment, provided its shareholders with its year-end 2023 business and Company update.
|
Zomedica Announces Publication of Research Validating Better Patient Acceptance of PulseVet(R) Electro-hydraulic Shock Wave Therapy without Sedation Utilizing Novel “X-Trode” Handpiece
Zomedica (NYSE American: ZOM), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, announced the publication of an article validating the ability to better utilize PulseVet electro-hydraulic shock wave therapy in canine patients without sedation.
|
|
|
Small Stocks Big Money™ Podcasts
|
|
|
Upcoming Events |
|
|
|
NASDAQ: BIAF - bioAffinity Technologies |
4:15pm Eastern |
bioAffinity Technologies addresses the urgent need for noninvasive, accurate early-stage cancer diagnosis and broad-spectrum cancer treatments. |
|
|
|
|
NASDAQ: SPI - SPI Energy |
4:15pm Eastern |
SPI Energy is a global renewable energy company and provider of solar storage and electric vehicle (EV) solutions that was founded in 2006 in Roseville, California and is headquartered in McClellan Park, California. |
|
|
|
|
NASDAQ: ASPI - ASP Isotopes |
4:15pm Eastern |
ASP Isotopes is an isotope enrichment company utilizing technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with low atomic masses. |
|
|
Archive Events |
|
|
|
NASDAQ: RVPH - Reviva Pharmaceuticals |
Meeting Duration 45 minutes |
Reviva is a Phase 3 clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. |
|
|
Lesson of the Week
Mitigate Risk by Buying Small-Caps in Bunches
|
|
|
MidSouth Week in Review
Gold hit 2089 from its recent 1996 level. The 30-year bond yield dropped below 4% from its recent 5%+ level.
|
|
|
You are receiving this email because your email is subscribed to our mailing list.
Click here to update your subscription or unsubscribe your email address.
Copyright © 2024 Redchip Companies, Inc. All rights reserved.
|
© 2024 Redchip Companies, Inc. All rights reserved
|
|
|
|
|